|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||35.87 - 36.75|
|52 Week Range||35.04 - 85.83|
|PE Ratio (TTM)||-11.38|
|Earnings Date||Jan 31, 2017 - Feb 6, 2017|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||66.64|
Categories: Fundamental Analysis Yahoo FinanceClick here to see latest analysis Capitalcube gives Mallinckrodt Plc a score of 50. Our analysis is based on comparing Mallinckrodt Plc with the following peers – Johnson & Johnson, Mylan N.V., Zogenix, Inc., Depomed, Inc., Teva Pharmaceutical Industries Limited Sponsored ADR and General Electric Company (JNJ-US, MYL-US, ZGNX-US, DEPO-US, TEVA-US and GE-US). Investment Outlook ... Read more (Read more...)
Mallinckrodt undertaking strategic acquisitions and divestitures to evolve as a high-performing specialty pharmaceutical company.
STAINES-UPON-THAMES, United Kingdom , Aug. 15, 2017 /PRNewswire/ -- Mallinckrodt Pharmaceuticals (NYSE: MNK), a leading global specialty pharmaceutical company, will present on Tuesday, Sept. 12, 2017 ...